Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases

Table 2 Protocols of intraarterial chemotherapy based on CTC chemosensitivity, and RECIST 1.1 responses

Pt	IV-CTCs	Intraarterial chemotherapy protocols			Response in association with targeted therapy
		Drug	% CTC chemosensitivity	Dose administered
1R	12.2/ml	MMC	82	25 mg/m²	PR
2R	16.2/ml	5-FU	70	100 mg/m²	PR
2R	16.2/ml	OX	72	80 mg/m²	PR
3R	8.4/ml	MMC	80	25 mg/m²	PR
		OX	75	80 mg/m²
		RAL	70	3 mg/m²
4R	12.2/ml	MMC	70	25 mg/m²	PR
		CIS	70	70 mg/m²
		RAL	70	3 mg/m²
5R	7.5/ml	MMC	80	25 mg/m²	PR
5R	7.5/ml	RAL	70	3 mg/m²	PR
6R	6.9/ml	MMC	80	25 mg/m²	PR
6R	6.9/ml	RAL	75	3 mg/m²	PR
7R	15.1/ml	ALK	70	30 mg/m²	PR
7R	15.1/ml	CAR	75	100 mg/m²	PR
8R	16.3/ml	ALK	75	30 mg/m²	PR
8R	16.3/ml	CAR	75	100 mg/m²	PR
9R	8.9/ml	OX	70	80 mg/m²	PR
10R	10/ml	OX	70	80 mg/m²	PR
10R	10/ml	MMC	75	25 mg/m²	PR
11R	9.5/ml	OX	70	80 mg/m²	PR
11R	9.5/ml	MMC	75	25 mg/m²	PR
12R	8.9/ml	OX	75	80 mg/m²	PR
12R	8.9/ml	MMC	75	25 mg/m²	PR
13R	7.5/ml	MMC	80	25 mg/m²	PR
14R	8.9/ml	MMC	82	25 mg/m²	PR
15R	6.9/ml	MMC	75	25 mg/m²	PR
16R	12.2/ml	MMC	82	30 mg/m²	PR
17R	16.2/ml	5-FU	60	600 mg/m²	PR
17R	16.2/ml	OX	72	150 mg/m²	PR
18R	7.5/ml	OX	75	80 mg/m²	SD
18R	7.5/ml	IRI	80	100 mg/m²	SD
19R	9/ml	MMC	85	25 mg/m²	SD
20R	8.4/ml	OX	85	80 mg/m²	SD
21R	9.7/ml	MMC	83	25 mg/m²	SD
22R	6.9/ml	MMC	80	25 mg/m²	SD
23R	9.8/ml	MMC	75	25 mg/m²	SD
24R	16.2/ml	DOX	72	35 mg/m²	SD
24R	16.2/ml	OX	65	80 mg/m²	SD
25R	9.8/ml	MMC	70	25 mg/m²	SD
25R	9.8/ml	RAL	70	3 mg/m²	SD
26R	8.9/ml	MMC	80	25 mg/m²	SD
27R	6.9/ml	MMC	80	25 mg/m²	SD
28 L	9.4/ml	MMC	85	25 mg/m²	SD
29 L	16.2/ml	MMC	80	25 mg/m²	SD
30 L	7.5/ml	OX	75	150 mg/m²	SD
30 L	7.5/ml	IRI	80	200 mg/m²	SD
31 L	10/ml	IRI	90	200 mg/m²	SD
32 L	16.2/ml	IRI	80	200 mg/m²	SD
33 L	7.5/ml	MMC	81	30 mg/m²	SD
34 L	9.8/ml	MMC	70	30 mg/m²	SD
35 L	9.9/ml	MMC	75	30 mg/m²	SD
35 L	9.9/ml	OX	70	150 mg/m²	SD
36 L	6.9/ml	MMC	80	30 mg/m²	PD

Pt Patient, R Patient with unresectable refractory recurrent rectal cancer, L Patient with unresectable refractory colo-rectal cancer liver metastases, IV-CTCs Isolated viable circulating tumor cells in patient blood prior to culture, 5-FU 5 fluorouracil, MMC Mitomycin, IRI Irinotecan, OX Oxaliplatin, RAL Raltitrexed, DOX Doxorubicin, ALK Alkeran, CIS Cisplatin, CAR Carboplatin, PR Partial response, SD stable disease, PD Progressive disease

ISSN: 1471-2407